Nutritional and Metabolic Diseases

441 trials 157 recruiting

Filter these 441 trials by phase, country and sponsor.

Open in Search →

Effects of AZD5004 in adults who are living with obesity or overweight with at least 1 weight-related medical condition Ended

2024-513691-18-00 Participants living with Obesity or Overweight with at 4 2024-12-11
A study investigating the effect of different approved medications on how the body processes the study compound RO7795081. RO7795081 is a ne… Ended

2024-517360-37-00 Type 2 Diabetes and obesity 3 2024-11-22
An open label, balanced, randomized, single dose, two treatment, two period, two sequence, crossover, bioequivalence study comparing Empagli… Ended

2024-513340-28-00 Diabetes 2 2024-11-19
A research study of a new medicine NNC0363-1063 in healthy participants and participants with type 1 diabetes Ended

2024-511808-17-00 Type 1 diabetes mellitus 1 2024-10-31
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE ASCENDING DOSE PHASE 1 STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PH… Ended

2024-514871-17-00 Obesity 1 2024-10-29
Dasatinib and quercetin, a combination of senolytics to treat fibrotic non-alcoholic fatty liver disease; The TRUTH study Ended

2024-517593-21-00 MASLD 4 2024-10-14
Bioequivalence clinical trial of dapagliflozin 10 mg tablets, after a single oral dose administration to healthy volunteers under fasting co… Ended

2024-515238-34-00 Diabetes 2 2024-10-10
A Study to Evaluate the Effects of Various Degrees of Hepatic Impairment on the Pharmacokinetics of A Single Subcutaneous Dose Of RO7434656,… Ended

2023-508270-29-01 Hepatic Impairment 3 2024-09-24
CK-0045 proof-of-concept study Ended

2024-514191-41-00 Type 2 diabetes and Obesity 4 2024-09-16
A Phase 2 Parallel Group Study in Adults with Type 2 Diabetes to evaluate Efficacy and Safety of GL0034 Ended

2024-513279-41-00 Type 2 diabetes mellitus 4 2024-09-06
A research study to see how well different doses of CagriSema help people with excess body weight lose weight Ended

2023-509273-24-00 Obesity 5 2024-09-05
A study to test whether BI 456906 (survodutide) influences the amount of bupropion, caffeine and midazolam in the blood in people with overw… Ended

2024-512332-29-00 Overweight 3 2024-09-05
Clinical study to evaluate the efficacy and safety of Pioglitazone co-administration in patients with type II diabetes with insufficient gly… Ended

2023-508924-36-00 Type 2 diabetes mellitus (T2DM) 5 2024-08-20
Effects of NNC0194-0499, cagrilintide, and semaglutide alone or in combinations on liver damage and alcohol use in people with alcohol-relat… Ended

2023-508170-28-00 alcohol-related liver disease 4 2024-08-07
Personalized Treatment Optimization for Kidney Health in Type 2 Diabetes: A Remote Trial with Empagliflozin and Finerenone Ended

2023-508585-15-00 Albuminuria 6 2024-07-29
A research study comparing how well different doses of the medicine NNC0487-0111 lower blood sugar in people with type 2 diabetes Ended

2023-509412-28-00 Type 2 Diabetes 4 2024-07-26
A research study of how safe a new medicine called NNC0519‑0130 is and to test its effect in people living with excess body weight with or w… Ended

2024-512719-28-00 Obesity, Type 2 Diabetes with either overweight or obes 3 2024-07-25
REIMAGINE 1: A research study to see how much CagriSema lowers blood sugar and body weight compared to placebo in people with type 2 diabete… Ended

2022-502677-42-00 Type 2 diabetes 5 2024-07-24
Investigation of pharmacokinetics, safety and tolerability of a single subcutaneous dose of NNC0487-0111 in participants with various degree… Ended

2023-509961-19-00 Obesity and Diabetes mellitus Typ 2 3 2024-07-18
A study to evaluate the efficacy and safety of gliclazide MR in patients with type 2 diabetes inadequately controlled with dapagliflozin wit… Ended

2024-511408-18-00 Type 2 Diabetes inadequately controlled with dapagliflo 5 2024-07-15
Randomised, crossover bioequivalence clinical trial of linagliptin/metformin 2.5 mg/1000 mg film-coated tablets, after a single oral dose ad… Ended

2024-512310-18-00 diabetes 2 2024-07-08
A Phase 2 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of ARO-APOC3 in Adults with Dyslipidemia Ended

2024-511331-96-00 Mixed Dyslipidemia 4 2024-07-04
A research study looking into the effect of NNC05190130 on blood levels of a birth control pill and emptying of the stomach in women after m… Ended

2023-507973-16-00 Healthy postmenopausal females (Type 2 Diabetes) 3 2024-07-04
Double-blind, placebo-controlled clinical trial to determine the effect of Patiromer on vascular function and its relationship with mineral … Ended

2023-503941-69-00 Chronic kindney disease 4 2024-07-04